Advertisement
Advertisement
CTXR
Citius Pharmaceuticals Inc. Common
0.73
USDSponsored
+0.05
+7.39%
Aug 11, 12:58 UTC -4
Open
CTXR Earnings Reports
Positive Surprise Ratio
CTXR beat 9 of 27 last estimates.
33%
Next Report
Date of Next Report
Dec 21, 2026
Estimate for Q4 26 (Revenue/ EPS)
$18.67M
/-$0.36
Implied change from Q3 26 (Revenue/ EPS)
--
/--
Implied change from Q4 25 (Revenue/ EPS)
--
/-50.00%
Citius Pharmaceuticals Inc. Common earnings per share and revenue
On Aug 10, 2026, CTXR reported earnings of -- USD per share (EPS) for Q3 26, -- the estimate of -0.01 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 15.10 million, with a --% difference.
Looking ahead to Q4 26, -- analysts forecast an EPS of -0.36 USD, with revenue projected to reach 18.67 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Actinium Pharmaceuticals, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.22
Actual
$0.89
Surprise
+502.71%
Kiora Pharmaceuticals, Inc. Common Stock
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.63
Actual
-$0.34
Surprise
+46.24%
AIM ImmunoTech Inc.
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.17
Actual
-$0.43
Surprise
-150.44%
Oruka Therapeutics, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.52
Actual
-$0.55
Surprise
-4.62%
Amylyx Pharmaceuticals, Inc. Common Stock
Report Date
Aug 06, 2026 For Q2 26
Estimate
-$0.36
Actual
-$0.39
Surprise
-5.95%
Harrow, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.34
Surprise
-85.19%
Silence Therapeutics Plc - ADR
Report Date
Aug 10, 2026 For Q2 26
Estimate
-Actual
-$0.26
Surprise
-
Minerva Neurosciences, Inc
Report Date
Aug 07, 2026 For Q2 26
Estimate
-$0.11
Actual
-$0.17
Surprise
-44.93%
Tonix Pharmaceuticals Holding Corp.
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$2.75
Actual
-$2.44
Surprise
+11.29%
Fractyl Health, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.13
Actual
-$0.12
Surprise
+12.85%
FAQ
What were Citius Pharmaceuticals Inc. Common's earnings and revenue for the latest quarter Q3 2026?
For Q3 2026, Citius Pharmaceuticals Inc. Common reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to Citius Pharmaceuticals Inc. Common's Q3 2026 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is Citius Pharmaceuticals Inc. Common expected to report next?
The next earning report is scheduled for Dec 21, 2026.
What are the forecasts for Citius Pharmaceuticals Inc. Common's next earnings report?
Based on --
analysts, Citius Pharmaceuticals Inc. Common is expected to report EPS of -$0.36 and revenue of $18.67M for Q4 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement